Ascentage Pharma Group International (AAPG) Retained Earnings (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Retained Earnings for 3 consecutive years, with -$988.8 million the latest figure, recorded in Q4 2025.

• Quarterly Retained Earnings fell 23.09% year-over-year to -$988.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$988.8 million (down 23.09% YoY) and the FY2025 annual result came in at -$1.0 billion, down 26.86% from the prior year.
• Retained Earnings fell to -$988.8 million in Q4 2025 per AAPG's latest filing, from -$803.4 million in the prior quarter.
• Over the last five years, Retained Earnings for AAPG reached as high as -$745.1 million in Q4 2023 and fell as low as -$988.8 million in Q4 2025.
• A 3-year average of -$845.8 million and a median of -$803.4 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2024 — Retained Earnings retreated 7.81% — and 2025, when it retreated 23.09%.
• Year by year, Retained Earnings stood at -$745.1 million in 2023, then decreased by 7.81% to -$803.4 million in 2024, then fell by 23.09% to -$988.8 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$988.8 million, -$803.4 million, and -$745.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.